$1.06 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 75.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MYL | Buy | MYLAN INC | $63,686,000 | +23.5% | 1,400,000 | +40.0% | 5.98% | +77.2% |
| MASI | Buy | MASIMO CORP | $57,456,000 | +33.8% | 2,700,000 | +48.4% | 5.40% | +91.9% |
| GHDX | Buy | GENOMIC HEALTH INC | $56,620,000 | +19.8% | 2,000,000 | +15.9% | 5.32% | +71.8% |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $55,164,000 | – | 1,200,000 | +100.0% | 5.18% | – |
| 5100PS | Buy | VOLCANO CORPORATION | $53,732,000 | -3.1% | 5,050,000 | +60.3% | 5.05% | +38.9% |
| ESRX | New | EXPRESS SCRIPTS HLDG CO | $49,441,000 | – | 700,000 | +100.0% | 4.65% | – |
| KERX | Buy | KERYX BIOPHARMACEUTICALS INC | $48,125,000 | +4.3% | 3,500,000 | +16.7% | 4.52% | +49.6% |
| GSK | New | GLAXOSMITHKLINE PLCcall | $45,970,000 | – | 1,000,000 | +100.0% | 4.32% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $44,924,000 | – | 400,000 | +100.0% | 4.22% | – |
| OFIX | Buy | ORTHOFIX INTL N V | $37,467,000 | +770.9% | 1,210,164 | +919.7% | 3.52% | +1148.6% |
| ARIA | Buy | ARIAD PHARMACEUTICALS INC | $32,400,000 | +1.7% | 6,000,000 | +20.0% | 3.04% | +45.9% |
| WW | Buy | WEIGHT WATCHERS INTL INC NEW | $27,440,000 | +60.1% | 1,000,000 | +17.6% | 2.58% | +129.7% |
| AMAG | New | AMAG PHARMACEUTICALS INC | $23,932,000 | – | 750,000 | +100.0% | 2.25% | – |
| SQNM | Buy | SEQUENOM INC | $23,760,000 | -2.5% | 8,000,000 | +27.0% | 2.23% | +39.7% |
| BRKR | Buy | BRUKER CORP | $18,515,000 | +52.6% | 1,000,000 | +100.0% | 1.74% | +118.9% |
| WCG | New | WELLCARE HEALTH PLANS INC | $14,190,000 | – | 235,174 | +100.0% | 1.33% | – |
| OTIC | New | OTONOMY INC | $13,752,000 | – | 573,000 | +100.0% | 1.29% | – |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $13,080,000 | -32.4% | 12,000,000 | +9.1% | 1.23% | -3.2% |
| CCRN | Buy | CROSS CTRY HEALTHCARE INC | $9,290,000 | +78.6% | 1,000,000 | +25.3% | 0.87% | +156.0% |
| PTCT | New | PTC THERAPEUTICS INC | $6,960,000 | – | 158,149 | +100.0% | 0.65% | – |
| INO | New | INOVIO PHARMACEUTICALS INC | $2,462,000 | – | 250,000 | +100.0% | 0.23% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.